Extended linifanib therapy in patients with advanced solid tumors in a phase I trial. Background: BNC105P is a novel agent which inhibits tubulin polymerization and acts as a VDA. BNC105P is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results